Biological properties of human skeletal myoblasts genetically modified to simultaneously overexpress the pro-angiogenic factors vascular endothelial growth factor-A and fibroblast growth factor-4.
Myocardial infarction results in cardiomyocyte loss and may eventually lead to cardiac failure. Skeletal myoblast transplantation into the scar area may compensate for this observed cell loss by strengthening the weakened myocardium and inducing myogenesis. Moreover, skeletal myoblasts may serve as potential transgene carriers for the myocardium (i.e., delivering pro-angiogenic factors, which may potentially improve blood perfusion in infarcted heart). We examined the influence of the simultaneous overexpression of two potent pro-angiogenic factors, fibroblast growth factor-4 (FGF-4) and vascular endothelial growth factor (VEGF), on human primary myoblast proliferation, cell cycle, resistance to hypoxic stress conditions and myogenic gene expression, as well as the induction of pro-angiogenic activities. We used a bicistronic plasmid vector encoding two factors introduced via an efficient myoblast electroporation method. The levels of overexpressed proteins were assessed, and their functionality at capillary formation was evaluated. This combined approach led to a high level of non-viral transient overexpression of both pro-angiogenic proteins, which proved to be potent regulators of blood vessel development assayed in capillary formation tests. We demonstrated in in vitro conditions that the transfection of human skeletal myoblasts with both FGF-4 and VEGF did not affect their basic biological properties such as the cell cycle, proliferation or expression of myogenic lineage-specific genes, and the modified cells adapted to oxidative stress conditions. Overall, the results obtained suggest that the applied combined approach with the use of two pro-angiogenic genes overexpressed in skeletal muscle stem cells may be an interesting alternative for the effective therapy of myocardial infarction in animal models and/or prospective clinical trials.
Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland. kurpimac@man.poznan.pl.
A
A
Zimna
A
A
Janeczek
N
N
Rozwadowska
M
M
Fraczek
P
P
Kucharzewska
M
M
Rucinski
T
T
Mietkiewski
M
M
Kurpisz
D002453:Cell Cycle; D049109:Cell Proliferation; D018274:Electroporation; D051519:Fibroblast Growth Factor 4 / Q000378:metabolism*; D015870:Gene Expression; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism; D006801:Humans; D032448:Myoblasts, Skeletal / Q000378:metabolism*; D009203:Myocardial Infarction / Q000628:therapy; D018919:Neovascularization, Physiologic; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
C496445:FGF4 protein, human; D051519:Fibroblast Growth Factor 4; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A